RONGTA TECH (09881) suggests the removal of Luo Bingxian Yongdao from the position of company auditor.
Rongda Technology (09881) announced that, pending the approval of relevant resolutions at the upcoming special shareholders' meeting, Luo Bingxiang Yungdao will be removed from his position as the company's auditor. Luo Bingxiang Yungdao has been appointed as the company's auditor since its preparation for listing on the Hong Kong Stock Exchange, and has been further appointed since the company's listing. His term will continue until the end of the company's first annual general meeting of shareholders.
RONGTA TECH (09881) has announced that after the relevant resolutions are passed at the upcoming special shareholders' meeting, Luo Bingxian Yongdao will be removed from the position of the company's auditor. Luo Bingxian Yongdao has been appointed as the company's auditor since its preparation for listing on the Hong Kong Stock Exchange, and has been further appointed since the company's listing. His term will continue until the end of the company's first annual shareholders' meeting.
The company is currently searching for a suitable candidate to fill the temporary vacancy of the auditor caused by the proposed removal. Once a replacement candidate is confirmed, the company will issue a separate announcement. Currently, the audit work has been fully suspended. Once a new auditor is appointed, the company will continue to make every effort to complete the audit procedures as soon as possible. The company will timely issue further announcements on any significant progress in the audit process, including the expected completion date of the audit and the expected date of publication of the annual performance (as applicable).
Related Articles

Buying low on Shenzhen Hepalink Pharmaceutical Group (09989) for two consecutive months, will the Hong Kong Stock Connect funds soon witness the reversal of the heparin cycle?

New Stock News | Leading supply chain company Andes Zhilian's Hong Kong IPO prospectus updated, achieving double high increase in revenue and net profit.

How strong is the demand for SpaceX (SPCX.US) IPO? Oversubscribed subscriptions, "greenshoe" exemption from commission, and options expected to open next week!
Buying low on Shenzhen Hepalink Pharmaceutical Group (09989) for two consecutive months, will the Hong Kong Stock Connect funds soon witness the reversal of the heparin cycle?

New Stock News | Leading supply chain company Andes Zhilian's Hong Kong IPO prospectus updated, achieving double high increase in revenue and net profit.

How strong is the demand for SpaceX (SPCX.US) IPO? Oversubscribed subscriptions, "greenshoe" exemption from commission, and options expected to open next week!

RECOMMEND





